U-251 MG Cells were plated in 96 well plates as described above and left to adhere overnight. Cells were pre-treated for 1 h with either zVAD-FMK; caspase inhibitor (BD Bioscience, Oxford, England), SP600125; JNK inhibitor, SB203580; p38 MAP Kinase Inhibitor (Sigma Aldrich, Arklow, Ireland), U0126; MEK1 and MEK2 Kinase Inhibitor (Sigma Aldrich, Arklow, Ireland), chloroquine or 3-methyladenine (3-MA), autophagy inhibitors (Sigma Aldrich, Arklow, Ireland) after which the UA standard (IC50) was added to each well. Cell viability was assessed 48 h later using Alamar Blue cell viability assay.
P38 map kinase inhibitor
Manufactured by Merck Group
Sourced in Ireland
The P38 MAP Kinase Inhibitor is a laboratory reagent used in research applications. It functions as a selective inhibitor of the p38 mitogen-activated protein (MAP) kinase signaling pathway. The p38 MAP kinase is involved in various cellular processes, including inflammation, cell growth, and differentiation.
Automatically generated - may contain errors
Lab products found in correlation
Caspase inhibitor, by BD (1 mentions)
Z vad fmk, by BD (1 mentions)
Human recombinant epidermal growth factor, by Merck Group (1 mentions)
Recombinant human r spondin 1, by Thermo Fisher Scientific (1 mentions)
Matrigel, by Corning (1 mentions)
48 well culture plate, by Corning (1 mentions)
Nicotinamide, by Merck Group (1 mentions)
Recombinant human noggin, by R&D Systems (1 mentions)
2 protocols using p38 map kinase inhibitor
1
Cytotoxicity Evaluation of UA in U-251 MG Cells
2
3D Intestinal Crypt Culture Protocol
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Intestinal crypts were cultured three-dimensionally as described previously.8 (link),9 (link),74 (link),75 Briefly, the isolated crypts were pelleted with 3 quick spins, resuspended in Matrigel (Corning), and plated in 48-well culture plates (Corning). After incubation at 37°C for 15 minutes, 250 μL of maintenance medium (50% Wnt3a-conditioned medium [ATCC#CRL-2647, Manassas, VA]), 50% 2× basal medium supplemented with 50 ng/mL recombinant human epidermal growth factor (Sigma-Aldrich), 100 ng/mL recombinant human noggin (R&D Systems, Minneapolis, MN), 500 ng/mL recombinant human R-spondin 1 (PeproTech, Cranbury, NJ), 10 mmol/L nicotinamide (Sigma-Aldrich), 10 μmol/L p160ROCK inhibitor (Y27632; Selleckchem, Houston, TX), 10 μmol/L p38 MAP kinase inhibitor (SB202190; Sigma-Aldrich), and 10 nmol/L PGE2 (Cayman Chemical, Ann Arbor, MI). GSK3 inhibitor (CHIR99021; Stemgent, Cambridge, MA) was added to the medium during the first 2 days.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!